Ola Landgren, MD, PhD and the University of Miami hosted a meeting on the current state of MRD testing in multiple myeloma. The event deeply covered topics that showed MRD testing being used in clinical trials, how the FDA looks at MRD testing as a potential clinical trial end point and types of MRD testing. The event was the first that was supported by all myeloma advocacy groups including HealthTree for Multiple Myeloma, the IMF and MMRF. 

Watch the Recording

Topics included: 

Current Era of MRD Testing

• MAIA Study: Sustained MRD Status in Non-Transplant Eligible Patients, Nizar Bahlis, MD, Arnie Charbonneau Cancer Institute, Calgary, Canada
• DETERMINATION Study: Upfront vs. Delayed Transplant by MRD Status, Paul Richardson, MD, Dana Farber Cancer Institute
• CASTOR Study: MRD Status in Relapsed/Refractory Myeloma, Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
• Sustained MRD Negativity on Maintenance Therapy, Urvi Shah, MD, Memorial Sloan Kettering Cancer Center
• Patient Perspectives on MRD Testing in Myeloma, Yelak Biru, International Myeloma Foundation

Current and Emerging Technologies for Tracking MRD in Myeloma

• Mass-specusing MALDI-TOF, BindingSite Techniology, Niels Weinhold, MD, Heidelberg University, Heidelberg, Germany
• Whole Genome Sequencing of Circulating Tumor Cells, Jean-Baptiste Alberge, PhD, Dana Farber Cancer Institute
• Individualized Serum Peptides, Sebia Technology, Katie Thoren, University of Miami
• VDJ Tracking in Bone Marrow and Peripheral Blood, Adaptive Technology, Malin Hultcrantz, MD, Memorial Sloan Kettering Cancer Center
• Perspectives on Available and New MRD Assays in Myeloma, George Mulligan, MMRF

Fireside Chat with the FDA: MRD in Myeloma, Today and Tomorrow

• Nicole Gormley, MD, Food and Drug Administration (FDA)

Treatment Decisions Based on MRD in Myeloma

• Update from the MASTER trial, Licano Costa, MD, UAB School of Medicine
• University of Chicago Treatment Cessation Study, Benjamin Derman, MD, University of Chicago
• MSKCC Treatment Cessation Study, Neha Korde, Memorial Sloan Kettering Cancer Center
• Role of Normalization of Bone Marrow Microenvironment, David Coffey, MD, Sylvester Comprehensive Cancer Center
• Using MRD Testing in the Real World, Jennifer Ahlstrom, HealthTree Foundation for Multiple Myeloma

We highly recommend you watching the program in the link below. 

Watch the Recording